治疗前血浆中胰岛素样生长因子（IGF）水平用于识别乳腺癌：一项病例对照研究。
Insulin-like growth factor (IGF) levels in pre-treatment plasma identifying breast cancer: A case control study.
作者信息
Alizadeh Sadighi Sarvin, Rostami Nematollah, Tohidi Maryam, Mashayekhi Mahbobeh
机构信息
Department of Internal Medicine, Clinical Research Development Center at Modarres Hospital, Shahid Beheshti University of Medical Science, Tehran, Iran.
Department of Hematology, Modarres Hospital, Shahid Beheshti University of Medical Science, Tehran, Iran.
出版信息
Caspian J Intern Med. 2024 Sep 7;15(4):706-712. doi: 10.22088/cjim.15.4.706. eCollection 2024 Fall.
BACKGROUND
Diabetes (primarily type 2) is linked to a higher risk of breast cancer. Insulin-like growth factor (IGF) is one of the most important factors that affects mitosis and thus inhibits apoptosis. The purpose of this study was to compare the pre-treatment insulin-like growth factor (IGF) levels in breast cancer against normal population.
METHODS
In this case-control study, 60 patients with breast cancer and 60 healthy controls were enrolled in 2017 and 2018 at Tehran's Shahid-Modarres Hospital. In this study, the blood sugar of the patients was examined before entering the study, and the age of the patients was also within the age limit of 18 to 70 years. They were studied to determine the relationship between insulin-like growth factor (ELISA method) and breast cancer.
RESULTS
Both groups have similar IGF-1 levels (Ctrl and Case) (P= 0.188). But, IGF-2 levels were significantly higher in breast cancer patients (373.4 vs. 317.3 ng/ml), (P=0.0001).
CONCLUSION
According to our study, IGF-2 may serve as a prognostic biomarker and potential therapeutic target for breast cancer. However, further investigation is needed to validate this claim.
背景
糖尿病（主要是2型糖尿病）与患乳腺癌的风险较高有关。胰岛素样生长因子（IGF）是影响有丝分裂并因此抑制细胞凋亡的最重要因素之一。本研究的目的是比较乳腺癌患者与正常人群治疗前的胰岛素样生长因子（IGF）水平。
方法
在这项病例对照研究中，2017年和2018年在德黑兰的沙希德 - 莫达雷斯医院招募了60例乳腺癌患者和60名健康对照者。在本研究中，在患者进入研究前检查其血糖，并且患者年龄也在18至70岁的年龄范围内。研究确定胰岛素样生长因子（酶联免疫吸附测定法）与乳腺癌之间的关系。
结果
两组的IGF - 1水平相似（对照组和病例组）（P = 0.188）。但是，乳腺癌患者的IGF - 2水平显著更高（373.4对317.3 ng/ml），（P = 0.0001）。
结论
根据我们的研究，IGF - 2可能作为乳腺癌的预后生物标志物和潜在治疗靶点。然而，需要进一步研究来验证这一说法。
Zotero 插件